Aclaris amends at-the-market stock sale agreement with Leerink, Cantor

Aclaris Therapeutics, Inc. disclosed in an 8-K filing that on August 6, 2026, the company entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. under which it may offer and sell shares of common stock from time to time at its own discretion through the two firms acting as sales agents.¹

Any shares sold under the new agreement will be issued pursuant to a registration statement on Form S-3.¹ The agreement amends and restates a prior sales agreement with Leerink and Cantor dated February 27, 2025, which had provided for the offer and sale of up to $100.0 million of common stock.¹

Under the terms disclosed, Leerink and Cantor may sell the stock through any method considered an "at the market offering" under Rule 415 of the Securities Act, using commercially reasonable efforts based on instructions from Aclaris, including any price, time, size or other conditions the company sets.¹ Aclaris will pay the two firms a commission equal to 3.0% of gross sales proceeds from any stock sold under the agreement.¹

The company also provided customary representations, warranties and covenants, and agreed to customary indemnification rights with the sales agents.¹ Importantly, Aclaris is not obligated to make any sales of common stock under the amended agreement,¹ and the offering will terminate when the agreement itself terminates according to its terms.¹

The filing noted it does not constitute an offer to sell or a solicitation to buy the securities described, nor any offer or sale in a state where it would be unlawful before registration or qualification under that state's securities laws.¹ The full agreement was filed as Exhibit 10.1 to the 8-K, signed by Chief Financial Officer Kevin Balthaser.